Plain-English translation of NCT06603363 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand how rosuvastatin, a cholesterol-lowering medication, affects fatty plaque buildup in your heart arteries when taken at a higher dose for a short time. This study uses advanced CT imaging to see whether the medication can change the makeup and structure of plaque — and whether those changes last even after you stop taking the higher dose. About 140 people will be enrolled, and half will receive the medication while half receive a placebo (a pill with no active ingredient).
Doctors know that cholesterol-lowering medications help prevent heart disease, but they don't fully understand how the medication actually changes plaque inside the arteries. This study could reveal whether short, intensive treatment has lasting benefits — a concept researchers call 'plaque memory.'
You likely qualify if…
You likely don't qualify if…
You will take one capsule by mouth once daily for 3 months — either the active medication or a placebo (you won't know which). You'll have CT imaging scans of your heart at the beginning and after 3 months to see how the plaque has changed. After 3 months, the placebo group will start standard cholesterol medication, and the active group will continue with a regular maintenance dose. Researchers will monitor your health and check blood work throughout the study.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Hungary